Cover Image

Age disparities in SGLT2 inhibitor prescription among people with type 2 diabetes: The role of frailty and sex

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Changyuan Yang, Petra Denig, Lynne Chepulis, Ryan G. Paul, Jung‐Im Shin, Ron T. Gansevoort, Priya Vart
Format:	Artículo Open Access
Published:	Wiley 2026
Subjects:	Diabetes, Obesity and Metabolism
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Inequity in adherence to empagliflozin and dulaglutide for type 2 diabetes in Aotearoa New Zealand
by: Sara Mustafa, et al.
Published: (2025)

Gender differences in the prescription of SGLT2 inhibitors in chronic kidney disease: A real‐world database study
by: Tatsuhiko Azegami, et al.
Published: (2025)

Predictors of diabetic ketoacidosis in patients with insulin‐deficient diabetes phenotype initiating SGLT2 inhibitors
by: Anat Tsur, et al.
Published: (2025)

Prevalence of SGLT2 inhibitor and GLP1 receptor agonist prescriptions in type 2 diabetes patients with and without chronic kidney disease: Analysis of an Australian primary care dataset
by: Hannah Wallace, et al.
Published: (2025)

Adherence to GLP ‐1 receptor agonists and SGLT2 inhibitors by out‐of‐pocket spending among Medicare beneficiaries with diabetes
by: Nicklas S. Klepser, et al.
Published: (2025)

Comparative effectiveness of combination therapy with SGLT ‐2 inhibitors and GLP ‐1 RAs compared with SGLT ‐2 inhibitors in individuals with type 2 diabetes: A prevalent new‐user cohort study
by: Gregor A. Maier, et al.
Published: (2026)

SGLT2 inhibitors are associated with a reduced incidence of atrial fibrillation in type 2 diabetes mellitus
by: Mark Luedde, et al.
Published: (2025)

Trends in obesity and glucagon‐like peptide‐1 receptor agonist prescriptions in type 1 diabetes in the United States
by: Yunwen Xu, et al.
Published: (2025)

Efficacy and safety of combination therapy using SGLT2 and DPP4 inhibitors to treat type 2 diabetes: An updated systematic review and meta‐analysis with focus on an Asian subpopulation
by: Myung Jin Kim, et al.
Published: (2025)

Benefits of combining SGLT2 inhibitors and pioglitazone on risk of MASH in type 2 diabetes—A real‐world study
by: Chi‐Ho Lee, et al.
Published: (2024)

Kidney outcomes with SGLT2 inhibitors in patients with diabetes and an insulin‐deficient phenotype: A real world analysis
by: Anat Tsur, et al.
Published: (2025)

Risk of acute pancreatitis with DPP ‐4 inhibitors versus SGLT2 inhibitors in medication‐naïve individuals with diabetes: A target trial emulation
by: Takashi Tatewaki, et al.
Published: (2026)

Clinical characteristics and outcomes of diabetes‐related ketoacidosis ( DKA ) in sodium‐glucose co‐transporter‐2 inhibitor ( SGLT2i ) users with type 2 diabetes
by: Angelica Sharma, et al.
Published: (2025)

Discontinuation of SGLT2i in people with type 2 diabetes following hospitalisation for heart failure: A cause for concern?
by: Tamara Y. Milder, et al.
Published: (2024)

An SGLT2 inhibitor, canagliflozin, reduces blood glucose level in the renal capillaries and protects the capillary network in the diabetic rats
by: Anqi Zhang, et al.
Published: (2025)

Ketosis and ketoacidosis in hospitalized patients receiving SGLT2 inhibitor therapy
by: Frank M. Gao, et al.
Published: (2025)

Concurrent SGLT2 inhibitor use in patients with type 2 diabetes hospitalised for high‐dose corticosteroid therapy: Mitigated iatrogenic hyperglycaemia
by: Kaori Ikeda, et al.
Published: (2025)

The importance of treatment sequencing with SGLT2 inhibitors and GLP ‐1 receptor agonists combination for kidney function preservation in type 2 diabetes
by: Mario Luca Morieri, et al.
Published: (2026)

Triple oral therapy with metformin, DPP ‐4 inhibitor, and SGLT2 inhibitor for adults with type 2 diabetes: Consensus recommendations of a Chinese expert panel (version 2025)
by: Miao Yu, et al.
Published: (2025)

One‐year usage patterns of SGLT ‐2 inhibitors and GLP ‐1 receptor agonists in individuals with type 2 diabetes in a real‐world population
by: Louise A. Donnelly, et al.
Published: (2025)

Cardiorenal outcomes and mortality with GLP ‐1 receptor agonists combined with SGLT2 inhibitors in type 2 diabetes: An updated systematic review and meta‐analysis
by: João Sérgio Neves, et al.
Published: (2025)

Effects of SGLT2 inhibitors on development and progression of kidney disease in Chinese patients with type 2 diabetes: A multicentre, prospective real‐world study
by: Yun Wang, et al.
Published: (2025)

SGLT2 inhibitor therapy and lower incidence of iron deficiency anaemia in patients with type 2 diabetes: A retrospective cohort study from Germany
by: Theresia Sarabhai, et al.
Published: (2025)

Efficacy and safety of GLP ‐1 receptor agonists and SGLT2 inhibitors as adjuncts to insulin in type 1 diabetes: Systematic review and meta‐analysis
by: Sama M. Abdel‐Rahman, et al.
Published: (2026)

SGLT2 inhibitor or metformin as standard treatment in early‐stage type 2 diabetes? Baseline data in SMARTEST , a novel, decentralised, register‐based randomised trial on prevention of diabetic complications
by: Jan W. Eriksson, et al.
Published: (2025)

Effectiveness of add‐on therapy with SGLT2 inhibitors or GLP ‐1 receptor agonists in adults with type 1 diabetes: A prospective DPV registry study
by: Christina Baechle, et al.
Published: (2024)

Sodium–glucose cotransporter 2 inhibitors reduce the risk of incident type 2 diabetes in people with heart failure without diabetes: An analysis of real‐world, cohort data
by: Alex E. Henney, et al.
Published: (2024)

Baseline HbA1c and dementia risk at SGLT2i initiation in type 2 diabetes
by: Jiaqiang Zhang, et al.
Published: (2025)

Developments in albuminuria testing: A key biomarker for detection, prognosis and surveillance of kidney and cardiovascular disease—A practical update for clinicians
by: Jelle M. Beernink, et al.
Published: (2025)

SGLT2 inhibitors reduce epicardial adipose tissue more than GLP ‐1 agonists or exercise interventions in patients with type 2 diabetes mellitus and/or obesity: A systematic review and network meta‐analysis
by: Yu Bao, et al.
Published: (2024)

Sodium‐glucose co‐transporter 2 inhibitors and obesity‐associated cancers in people with type 2 diabetes: A real‐world observational study
by: Testimony Ipaye, et al.
Published: (2026)

Effects of the SGLT2 inhibitor ipragliflozin and metformin on hepatic steatosis and liver fibrosis: Sub‐analysis of a randomized controlled study
by: Kiichi Hirayama, et al.
Published: (2025)

Effects of SGLT2 inhibitors across the spectrum of albuminuria in cardiovascular–kidney–metabolic conditions: A pooled analysis of randomised trials
by: João Pedro Ferreira, et al.
Published: (2025)

Regional disparities in type 2 diabetes prevalence and associated risk factors in the United States
by: Sulakshan Neupane, et al.
Published: (2024)

Sodium glucose co‐transporter 2 inhibitors versus dipeptidyl peptidase‐4 inhibitors and the risk of ventricular arrhythmia among patients with type 2 diabetes: A population‐based cohort study
by: Wang‐Choi Tang, et al.
Published: (2025)

Comparison of estimated glomerular filtration rate change with sodium‐glucose cotransporter‐2 inhibitors versus glucagon‐like peptide ‐1 receptor agonists among people with diabetes: A propensity‐score matching study
by: Yuta Suzuki, et al.
Published: (2024)

Renal outcomes with sodium‐glucose cotransporter 2 inhibitors in Japanese people with grade 3 chronic kidney disease and type 2 diabetes: Analysis of medical administrative databases
by: Hiroaki Iijima, et al.
Published: (2024)

Effects of insulin‐induced hypoglycaemia on cardiac function in people with type 1 and type 2 diabetes and people without diabetes
by: Therese Wilbek Fabricius, et al.
Published: (2025)

Geographic variation in sodium‐glucose cotransporter 2 inhibitor and glucagon‐like peptide‐1 receptor agonist use in people with type 2 diabetes in New South Wales, Australia
by: Juliana de Oliveira Costa, et al.
Published: (2024)

SGLT2 inhibition improves endothelium‐independent vasodilatory function in type 2 diabetes: A double‐blind, randomized, placebo‐controlled crossover trial
by: Didde Kidmose Kristensen, et al.
Published: (2024)